Pediatrics

The right pediatric program to deliver your medicine sooner.

Providing new treatments for children requires careful planning and expertise – with patient safety at the center of everything you do.

Solutions Therapeutics Pediatrics

Let expertise be your guide

Successfully navigating the road to developing and delivering pediatric products requires a specialized mix of scientific, therapeutic, regulatory and operational expertise to ensure your pediatric studies are successfully planned and executed.

From the earliest planning stages of clinical development, through launch and real-world assessment, pediatric expertise is key to ensuring you are asking the right questions to meet the specific needs of infants, children and adolescents.

From start to finish, we are here

At IQVIA, we are prepared to provide tailored, informed support throughout your journey. We can help

Develop your product’s Pediatric Investigation Plan (PIP) and/or Pediatric Study Plan (PSP)
Recommend alternative study designs through the use of modeling, simulation and real world data
Navigate complex and unique regulatory requirements for pediatric clinical research
Connect you to a network of specialized pediatric study sites
Identify, consent/assent and retain pediatric patients and their families throughout your program

Pediatric Center of Excellence

Experts from across IQVIA come together to help you conceptualize and execute your pediatric studies. The group is charged with advising on the conduct of pediatric programs to ensure the right strategy and the right level of oversight, counsel, training and collaboration is applied to your project. Identify the right path to fulfill pediatric safety requirements and deliver a product that meets the unique needs of infants, children and adolescents, from trial environments into their everyday lives.

>20 in-house pediatricians
>230 Clinical Research Associates
>60 sites in the Pediatrics & Rare Disease Network

Advancing Pediatric Cancer Research

The RACE for Children Act will have significant impact on cancer drug development. Among all ongoing cancer trials, more than 70% involve RACE-defined molecular target drugs, but only 6.9% appear to include pediatric-age participants, according to a new analysis conducted by the IQVIA Institute.

Learn more

Solutions you may be interested in

Rare Diseases

Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.

Site Identification

Identify the best performing sites for your trial in less time with new machine learning and predictive modeling methods.

Decentralized Trials

Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.

Pediatrics